Full or majority sale.
Defined terms, an efficient process, and liquidity at close.
Together, stronger.
N1 partners with exceptional physicians and practitioners to build enduring practices in elective care. We focus on medical aesthetics, plastic surgery, and longevity.
Independent practice has a structural ceiling.
The elective medicine market is consolidating. Well-capitalized platforms compete with structural advantages in purchasing, marketing, and talent. Each year, the cost of competing independently rises. Partnership with N1 changes that position.
Liquidity.
Partners realize cash at close, on a timeline of their choosing.
Operations.
A dedicated team assumes marketing, recruiting, revenue cycle, and technology from day one.
Purchasing power.
Group pricing on devices and injectables that independent practices cannot obtain alone.
Research.
Active research programs help partner practices evaluate and deploy new protocols first.
Ownership.
Partners hold equity in N1 and participate in the value of the entire platform.
Elective medicine is where care moves first.
New protocols, devices, and care models reach elective medicine years before they reach the hospital system. Longevity and preventive medicine are next. N1 conducts research, publishes its findings, and deploys the resulting protocols across the platform. Partner practices deliver them first.
We are not building to the existing standard of care. We intend to set the next one.
The composition of the platform is being determined now.
Institutional scale. Physician control.
Clinical authority remains with the physician. Medical judgment, treatment decisions, and the physician-patient relationship are preserved in explicit terms. The business is what we build together: operations, growth, and brand strategy, determined case by case.
Partnership period.
Retain full ownership while N1 operates the practice for 12 months. Transacting remains optional throughout.
Equity participation.
Roll equity into N1 and participate in the long-term value of the entire platform.
The structure follows the physician's objectives, stage of business, and stage of life.
The patient experience improves from day one.
Patients keep their physician, treatment plans, and relationship. Everything surrounding the visit improves: scheduling, intake, follow-up, and post-visit care tailored to the individual.
Patients of partner practices receive first access to new devices and therapeutics from the N1 research network. N1 contractually commits to measurable improvement in the patient experience within 90 days.
Physicians. Scientists. Operators.
Our multidisciplinary team has published research in Nature, built technology platforms used by millions, and advised on multi-billion-dollar M&A for leading global organizations. The individuals responsible for clinical standards are the same individuals building the company. Prospective partners meet the principals early in the process.
From first conversation to a definitive answer in 14 days.
Discussion.
Thirty minutes focused on your objectives. Confidential from the first conversation.
Review.
You provide financials under NDA. We model value as a buyer would and present the analysis in full.
Decision.
Within 14 days, receive an offer or a market-grade valuation report with specific recommendations.
The process concludes with either a transaction or a buyer-grade assessment of your practice, complimentary and yours to keep. Both outcomes carry value.
Straight answers.
Is N1 private equity?+
No. N1 is a partnership founded by physicians, scientists, and operators and built with permanent capital rather than a fund timeline. Partners may realize cash at close, retain clinical authority, and receive ownership in the platform.
Do I lose control?+
Not over medicine. Medical judgment, treatment decisions, and the physician-patient relationship remain with the physician and are stated explicitly in our agreements. N1 assumes the administrative work defined together.
What happens to my brand?+
We determine that together. Strong local brands may continue with N1's capital and operating resources behind them. In other markets, a unified brand may create greater long-term value. The decision is made practice by practice.
What happens to my team?+
Your team is a material part of the practice's value. Staffing, roles, benefits, and development are evaluated practice by practice, with clear terms established before any transaction.
What happens to my patients?+
They remain under physician-led care on treatment plans their physician approves. The surrounding experience improves through better scheduling, intake, follow-up, and post-visit care.
What if I am not ready to sell?+
Then do not sell. Begin with the 12-month partnership, retain full ownership while N1 strengthens the practice, and decide later from a position of greater strength.
What do I receive within 14 days?+
One of two outcomes: an offer with defined terms, or a market-grade valuation detailing what the practice is worth today, how a buyer would calculate it, and specific measures that could raise the figure. Both are complimentary.
Why is the valuation complimentary?+
Because the work earns the relationship. Some physicians take the report and conclude there. Enough choose to continue that the model works for us. There is no obligation.
How is a practice valued?+
We assess profitability, growth, patient retention, reputation, and operational quality using real financials and operating metrics. Every assumption is presented, not only the conclusion.
How does compensation work?+
Partners may realize value twice: first in cash at close under the structure selected, and again through equity participation in N1 at the platform level.
What does N1 do day to day?+
N1 supports growth marketing, recruiting and human resources, group purchasing, revenue cycle, finance, compliance, and technology. The practical result is more time devoted to patients.
Must I continue practicing?+
Most partners continue because the role returns its focus to patients. The expected commitment and any succession plan are structured jointly around each physician's goals.
Is my information confidential?+
Entirely. An NDA precedes financial review, access is limited to the transaction team, and no one contacts your staff, patients, or market.
Which practices qualify?+
Established, profitable practices in medical aesthetics, plastic surgery, dermatology, and longevity, led by founders who intend to continue building.
Why now rather than later?+
The ownership map of elective medicine is being drawn now. Practices that partner early help shape their markets and negotiate their terms before the landscape is set.
Why N1 rather than a direct sale?+
A direct sale typically delivers one payment. N1 can pair liquidity at close with an ongoing equity position in the platform, allowing partners to participate in the value they help create.
Who is behind N1?+
A multidisciplinary team of physicians, scientists, and operators whose work includes research published in Nature, technology platforms used by millions, and multi-billion-dollar M&A for leading organizations.
Begin a conversation.
One conversation. Under NDA. A definitive answer in 14 days. The leading practices in elective medicine are becoming one company, owned by the physicians who built them. We invite you to review the terms.
ConfidentialNo feesNo obligation
Still have questions? Contact us.